On November 18, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The DDR Inhibitors Summit is recognized as a premier global forum uniting translational scientists, clinicians, and biotechnology innovators working to advance next-generation DDR-targeted cancer therapies. The 2026 program will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, with a strong focus on translational strategies to accelerate clinical impact.
Prof. Daugaard will deliver a featured presentation titled:
"Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics"
His session will highlight Rakovina’s pivot to an AI-enabled drug discovery model and showcase studies of AI-designed DDR programs progressing through preclinical lead selection and toward development.
In addition to his presentation, Prof. Daugaard will participate in a fireside chat entitled "Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures" and a panel discussion on "Uniting Founders and Funders to Align Scientific Vision with Investment Strategy." In these sessions, he will join a distinguished group of global oncology leaders to discuss evolving DDR biology, resistance mechanisms, and next-generation clinical strategies.
"The DDR field is undergoing a profound shift, driven by new discoveries in DNA damage response biology, smarter combination strategies, and the integration of AI into early discovery," said Prof. Daugaard. "We are excited to contribute to the scientific dialogue shaping the future of targeted oncology, and to share how AI can accelerate the development of precisely engineered DDR therapeutics designed for clinical impact."
As a co-founder of Rakovina and an Associate Professor at the University of British Columbia, Prof. Daugaard brings deep expertise in cancer biology and therapeutic resistance, with a research focus on uncovering vulnerabilities in tumor survival pathways and advancing them toward targeted drug discovery. His participation in the 9th DDR Inhibitors Summit reinforces the momentum behind Rakovina’s AI-accelerated DDR pipeline and highlights the Company’s role within a collaborative global effort to deliver new therapeutic options for patients with difficult-to-treat cancers.
(Press release, Rakovina Therapeutics, NOV 18, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-president-cso-to-present-and-join-expert-panel-at-the-9th-annual-ddr-inhibitors-summit [SID1234660058])